Surgery Partners (NASDAQ:SGRY) re-affirms its 2022 Adjusted EBITDA guidance of $375M to $385M.
2022 revenue expected of $2.50B to $2.55B vs consensus of $2.52B.
Surgery Partners reaffirms FY22 guidance
Recommended For You
More Trending News
About SGRY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SGRY | - | - |
Surgery Partners, Inc. |